European Medicines Agency investigating Pandemrix

Officials with the European Medicines Agency are looking into the safety of the swine flu vaccine Pandemrix after reports surfaced that the treatment may be linked to a rare sleep disorder.

The vaccine, manufactured by GlaxoSmithKline, will be investigated due to reported cases of narcolepsy in Europe, reports. Officials in Finland have already decided to stop administering the swine flu treatment after the reports surfaced.

Health officials told that approximately 30 million people across Europe have already received the vaccine. To date, there have been 27 reported cases of the sleep disorder in Finland, Sweden, France, Germany and Norway that officials believe could be tied to the virus vaccine.

A European Medicines Agency spokesperson, who was not named in the report, told that, while the narcolepsy cases have been reported in temporal association with the use of the vaccine, it has yet to be determined whether the vaccine actually caused the sleep disorder.

Officials said they are examining the data to try to find evidence for a causal association.

GlaxoSmithKline officials said that they are also conducting their own investigation of their product.

“Information surrounding the reported cases remains limited at the current time,” an unnamed GlaxoSmithKline spokesperson told “GSK is conducting its own investigation in an effort to gather as much additional data as possible regarding the observed cases and is working closely with the regulatory authorities, including the European Medicines Agency.”